Donor side effects experienced under minimal controlled ovarian stimulation with in vitro maturation vs. conventional controlled ovarian stimulation for in vitro fertilization treatment

• Published in: F&S Science (Online) Vol. 5; no. 3; p. 242
• Main Authors: Marchante, Maria, Barrachina, Ferran, Piechota, Sabrina, Fernandez-González, Marta, Giovannini, Alexa, Smith, Trozalla, Kats, Simone, Paulsen, Bruna, González, Eva, Calvente, Virginia, Silvan, Ana, Abittan, Baruch, Klein, Joshua, Klatsky, Peter, Ordonez, Daniel, Kramme, Christian C
• Format: Journal Article
• Language: English
• Published: United States 01.08.2024
• Subjects: Adult; Female; Fertilization in Vitro - methods; Follicle Stimulating Hormone - administration & dosage; Follicle Stimulating Hormone - adverse effects; Follicle Stimulating Hormone - therapeutic use; Humans; In Vitro Oocyte Maturation Techniques - methods; Oocyte Retrieval - methods; Ovulation Induction - adverse effects; Ovulation Induction - methods; Retrospective Studies; minimal ovarian stimulation; side effects; hormonal injections; In vitro fertilization
• ISSN: 2666-335X
• DOI: 10.1016/j.xfss.2024.05.002

To evaluate oocyte retrieval experiences and side effects under minimally controlled ovarian stimulation (COS) treatment for in vitro maturation (IVM) of oocytes compared with conventional COS treatment. A retrospective survey study. Clinical in vitro fertilization treatment center. Data were collected from subjects undergoing minimal COS treatment (n = 110; 600-800 IU follicle-stimulating hormone) for IVM of oocytes and conventional COS treatment for egg donation (n = 48; 1,800-2,600 IU follicle-stimulating hormone) from April 2022 to November 2023. Minimal and conventional COS treatments. The most common side effects experienced during ovarian stimulation and after oocyte pick-up, satisfaction level, and the likelihood of recommending or repeating minimal or conventional COS. Statistical analysis included Mann-Whitney U test and χ tests, with a significance level. During minimal COS treatment, most subjects did not experience breast swelling (86%), pelvic or abdominal pain (76%), nausea or vomiting (96%), and bleeding (96%). After oocyte pick-up, the majority (75%) reported no pelvic or abdominal pain. The most common side effect was abdominal swelling (52%). Compared with conventional COS cycles, minimal COS subjects reported significantly less postretrieval pain, with 33% experiencing no pain (vs. 6%) and with a reduced severe level of pain (5% vs. 19%), leading to fewer subjects requiring pain medication (25% vs. 54%). Additionally, 85% of women were very satisfied with minimal stimulation treatment and would recommend or repeat the treatment. Reducing the hormonal dose for ovarian stimulation has a beneficial effect on subjects, suggesting the combination of minimal COS treatment with IVM techniques is a well-tolerated alternative for women who cannot or do not wish to undergo conventionally controlled ovarian hyperstimulation treatment.